Insulet (PODD) reported Q3 EPS of $0.45, $0.29 better than the analyst estimate of $0.16. Revenue for the quarter came in at $340.8 million versus the consensus estimate of $313.06 million.
GUIDANCE:
2022 Outlook
Revenue Guidance (in constant currency):
For the year ending December 31, 2022, the Company is raising its revenue growth guidance range to 18% to 19% (previously 14% to 17%). Revenue growth ranges by product line are:
Total Omnipod of 23% to 24% (previously 18% to 21%)
U.S. Omnipod of 30% to 31% (previously 23% to 26%)
International Omnipod of 11% to 12% (previously 9% to 12%)
Drug Delivery of (37)% to (35)% (previously (40)% to (35)%)
For the quarter ending December 31, 2022, the Company expects revenue growth of 11% to 14%. Revenue growth ranges by product line are:
Total Omnipod of 23% to 26%
U.S. Omnipod of 27% to 30%
International Omnipod of 15% to 18%
Drug Delivery of (100)% to (92)%